Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine + Alemtuzumab vs Fludarabine + Rituximab in Refractory/Relapsed CLL
NCT00086775Phase 2Completed
- Sponsor
- Bayer
- Start
- Jul 2003
- Primary completion
- Jun 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alemtuzumab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Bayer. Primary endpoint: Complete Response Rate. Started Jul 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00086775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086775.